Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
CleanMyMac Review
FBI searched for name of US senator facing foreign threat in latest improper use of intelligence database
Shadow Review
MrBeast's epic reply to Kai Cenat's $100K appeal at Sidemen Charity Match breaks Internet
15 of the best Photoshop courses you can take online for free
What we know about Threads, Meta's 'Twitter killer'
Tyler1 dubs Ludwig 'loser' as he declines his gaming event invite during livestream: ‘You have to move on’
Microsoft's Zune Returns From the Dead (as a Movie Giveaway)